Karin Moelling on Contribution to Cancer Research
  Karin Moelling     Biography    
Recorded: 06 Jun 2006

Well, I think, the most important gene out of my view is the gene product Raf kinase and that’s been one of the hot spots right now for finding therapeutics. I didn’t do a therapeutic screen that’s my old company life, they tested it in mice. That’s a follow up of my work. I’m not directly involved in it anymore, but I like to see that people can be treated this way.

Karin Moelling currently retired professor, still affiliated with the University of Zurich and the Max-Planck-Institute for Molecular Genetics in Berlin. She studied molecular biology at the University of Berkely, Califonia. She received her PhD at the Max-Planck-Institute for Virology at Tübingen in Germany. She did two post-doctoral research at the Robert Koch Institute in Berlin (1973-1975), and at the Institute of Virology, University Giessen. In 1977 she received her Habilitation at the University of Giessen in Biophysics on "Replication of retroviruses".

From 1976 till 1981 she was the Head of Independent Research Group at Max-Planck-Institute for Molecular Genetics in Berlin, Germany, on oncogenes, proto-oncogenes, cancer and HIV. In 1993 she became the Director of Institute of Medical Virology (IMV) and Full Professor at University of Zurich in Switzerland, she held this position till 2008. Between 2008-2009 she was Fellow of Institute of Advanced Study in Berlin and between 2008-2011 she became a Group Leader, Viruses and Cancer at University of Zurich.

Her research focus on retroviruses and cancer from molecular mechanisms to drug design. She is a Member of the European Molecular Biology Organization. She received several awards e.g. SwissAward in 2007, 4 prices: Czerny Price, Richtzenhain Price, Meyenburg Price and Ansman Price. She was Selected as Heisenberg Fellow in German Science Foundation.